Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Renalytix AI stock

Own Renalytix AI stock in just a few minutes.

Renalytix AI plc is a diagnostics & research business based in the US. Renalytix AI shares (RNLX) are listed on the NASDAQ and all prices are listed in US Dollars. Renalytix AI employs 8 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Renalytix AI

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RNLX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Renalytix AI share price

Use our graph to track the performance of RNLX stocks over time.

Renalytix AI shares at a glance

Information last updated 2021-04-23.
52-week range$9.91 - $32.12
50-day moving average $27.03
200-day moving average $19.38
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.26

Buy Renalytix AI shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Renalytix AI stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Renalytix AI financials

Revenue TTM $400,000
Gross profit TTM $0
Return on assets TTM -16.05%
Return on equity TTM -23.63%
Profit margin 0%
Book value N/A
Market capitalisation $1.1 billion

TTM: trailing 12 months

Shorting Renalytix AI shares

There are currently 352,050 Renalytix AI shares held short by investors – that's known as Renalytix AI's "short interest". This figure is 14.1% up from 308,557 last month.

There are a few different ways that this level of interest in shorting Renalytix AI shares can be evaluated.

Renalytix AI's "short interest ratio" (SIR)

Renalytix AI's "short interest ratio" (SIR) is the quantity of Renalytix AI shares currently shorted divided by the average quantity of Renalytix AI shares traded daily (recently around 169254.80769231). Renalytix AI's SIR currently stands at 2.08. In other words for every 100,000 Renalytix AI shares traded daily on the market, roughly 2080 shares are currently held short.

However Renalytix AI's short interest can also be evaluated against the total number of Renalytix AI shares, or, against the total number of tradable Renalytix AI shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Renalytix AI's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Renalytix AI shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Renalytix AI shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Renalytix AI.

Find out more about how you can short Renalytix AI stock.

Renalytix AI share dividends

We're not expecting Renalytix AI to pay a dividend over the next 12 months.

Renalytix AI share price volatility

Over the last 12 months, Renalytix AI's shares have ranged in value from as little as $9.907 up to $32.12. A popular way to gauge a stock's volatility is its "beta".

RNLX.US volatility(beta: 1.05)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Renalytix AI's is 1.0474. This would suggest that Renalytix AI's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Renalytix AI overview

Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom. .

Frequently asked questions

What percentage of Renalytix AI is owned by institutions?
Currently 14.567% of Renalytix AI shares are held by institutions.
How many people work for Renalytix AI?
Latest data suggests 8 work at Renalytix AI.
When does the fiscal year end for Renalytix AI?
Renalytix AI's fiscal year ends in June.
Where is Renalytix AI based?
Renalytix AI's address is: Avon House, Cardiff, United Kingdom, CF64 2EZ
What is Renalytix AI's ISIN number?
Renalytix AI's international securities identification number is: US75973T1016

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site